Utility of renal biopsy in the clinical management of renal disease

Kidney International

Volumn 85, Issue 5, 2014, Pages 1039-1048

  Dhaun, Neeraj ^a,b   Bellamy, Christopher O ^b   Cattran, Daniel C ^c   Kluth, David C ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Chronic kidney disease; Clinical nephrology; Kidney biopsy

Indexed keywords

ACUTE KIDNEY FAILURE; ANCA ASSOCIATED VASCULITIS; BLOOD TRANSFUSION; DIABETIC NEPHROPATHY; DISEASE CLASSIFICATION; DISEASE COURSE; FOCAL GLOMERULOSCLEROSIS; GLOMERULOSCLEROSIS; HEMATURIA; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY TRANSPLANTATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SAFETY; TREATMENT RESPONSE; AGE; BIOPSY; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; KIDNEY; KIDNEY DISEASES; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

AGE FACTORS; BIOPSY; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; KIDNEY; KIDNEY DISEASES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84899989164     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.512     Document Type: Review

References (97)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39: 1-266.
2. Chadban SJ, Briganti EM, Kerr PG et al. Prevalence of kidney damage in Australian adults: The AusDiab kidney study. J Am Soc Nephrol 2003; 14: 131-138.
3. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047.
4. Hallan SI, Coresh J, Astor BC et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 2006; 17: 2275-2284.
5. Wen CP, Cheng TY, Tsai MK et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet 2008; 371: 2173-2182.
6. Levey AS, de Jong PE, Coresh J et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011; 80: 17-28.
7. Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol 2002; 13: 37-40.
8. Collins AJ, Foley RN, Herzog C et al. United States Renal Data System, USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2011.
9. Iversen P, Brun C. Aspiration biopsy of the kidney. Am J Med 1951; 11: 324-330.
10. Fogo AB. Approach to renal biopsy. Am J Kidney Dis 2003; 42: 826-836.
11. Gerth J, Busch M, Illner N et al. Are tissue samples from two different anatomical areas of the kidney necessary for adequate diagnosis? Clin Nephrol 2010; 74: 258-265.
12. Whittier WL. Complications of the percutaneous kidney biopsy. Adv Chronic Kidney Dis 2012; 19: 179-187.
13. Roth R, Parikh S, Makey D et al. When size matters: diagnostic value of kidney biopsy according to the gauge of the biopsy needle. Am J Nephrol 2013; 37: 249-254.
14. Eiro M, Katoh T, Watanabe T. Risk factors for bleeding complications in percutaneous renal biopsy. Clin Exp Nephrol 2005; 9: 40-45.
15. Manno C, Strippoli GF, Arnesano L et al. Predictors of bleeding complications in percutaneous ultrasound-guided renal biopsy. Kidney Int 2004; 66: 1570-1577.
16. Nicholson ML, Wheatley TJ, Doughman TM et al. A prospective randomized trial of three different sizes of core-cutting needle for renal transplant biopsy. Kidney Int 2000; 58: 390-395.
17. Furness PN, Taub N, Assmann KJ et al. International variation in histologic grading is large, and persistent feedback does not improve reproducibility. Am J Surg Pathol 2003; 27: 805-810.
18. Birnholz JC, Kasinath BS, Corwin HL. An improved technique for ultrasound guided percutaneous renal biopsy. Kidney Int 1985; 27: 80-82.
19. Riehl J, Maigatter S, Kierdorf H et al. Percutaneous renal biopsy: comparison of manual and automated puncture techniques with native and transplanted kidneys. Nephrol Dial Transplant 1994; 9: 1568-1574.
20. Corapi KM, Chen JL, Balk EM et al. Bleeding complications of native kidney biopsy: a systematic review and meta-analysis. Am J Kidney Dis 2012; 60: 62-73.
21. Manno C, Bonifati C, Torres DD et al. Desmopressin acetate in percutaneous ultrasound-guided kidney biopsy: a randomized controlled trial. Am J Kidney Dis 2011; 57: 850-855.
22. Bairy M, Beleed K, Webb AT et al. Safety of outpatient kidney biopsy: one center's experience with 178 native kidney biopsies. Am J Kidney Dis 2008; 52: 631-632.
23. McMahon GM, McGovern ME, Bijol V et al. Development of an outpatient native kidney biopsy service in low-risk patients: a multidisciplinary approach. Am J Nephrol 2012; 35: 321-326.
24. Packham D, Fairley KF. Renal biopsy: indications and complications in pregnancy. Brit J Obstet Gynaecol 1987; 94: 935-939.
25. Chen HH, Lin HC, Yeh JC et al. Renal biopsy in pregnancies complicated by undetermined renal disease. Acta Obstet Gynecol Scand 2001; 80: 888-893.
26. Kuller JA, D'Andrea NM, McMahon MJ. Renal biopsy and pregnancy. Am J Obstet Gynecol 2001; 184: 1093-1096.
27. Day C, Hewins P, Hildebrand S et al. The role of renal biopsy in women with kidney disease identified in pregnancy. Nephrol Dial Transplant 2008; 23: 201-206.
28. Schena FP. Survey of the Italian Registry of Renal Biopsies. Frequency of the renal diseases for 7 consecutive years. The Italian Group of Renal Immunopathology. Nephrol Dial Transplant 1997; 12: 418-426.
29. Rivera F, Lopez-Gomez JM, Perez-Garcia R. Clinicopathologic correlations of renal pathology in Spain. Kidney Int 2004; 66: 898-904.
30. Covic A, Schiller A, Volovat C et al. Epidemiology of renal disease in Romania: a 10 year review of two regional renal biopsy databases. Nephrol Dial Transplant 2006; 21: 419-424.
31. Li LS, Liu ZH. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int 2004; 66: 920-923.
32. Nair R, Bell JM, Walker PD. Renal biopsy in patients aged 80 years and older. Am J Kidney Dis 2004; 44: 618-626.
33. Haas M, Spargo BH, Wit EJ et al. Etiologies and outcome of acute renal insufficiency in older adults: a renal biopsy study of 259 cases. Am J Kidney Dis 2000; 35: 433-447.
34. Moutzouris DA, Herlitz L, Appel GB et al. Renal biopsy in the very elderly. clin J Am Soc Nephrol 2009; 4: 1073-1082.
35. Bomback AS, Appel GB, Radhakrishnan J et al. ANCA-associated glomerulonephritis in the very elderly. Kidney Int 2011; 79: 757-764.
36. Parrish AE. Complications of percutaneous renal biopsy: a review of 37 years' experience. Clin Nephrol 1992; 38: 135-141.
37. John GT, Date A, Korula A et al. Nondiabetic renal disease in noninsulindependent diabetics in a south Indian Hospital. Nephron 1994; 67: 441-443.
38. Mak SK, Gwi E, Chan KW et al. Clinical predictors of non-diabetic renal disease in patients with non-insulin dependent diabetes mellitus. Nephrol Dial Transplant 1997; 12: 2588-2591.
39. Mazzucco G, Bertani T, Fortunato M et al. Different patterns of renal damage in type 2 diabetes mellitus: a multicentric study on 393 biopsies. Am J Kidney Dis 2002; 39: 713-720.
40. Sharma SG, Bomback AS, Radhakrishnan J et al. The modern spectrum of renal biopsy findings in patients with diabetes. Clin J Am Soc Nephrol 2013; 8: 1718-1724.
41. Caramori ML, Parks A, Mauer M. Renal lesions predict progression of diabetic nephropathy in type 1 diabetes. J Am Soc Nephrol 2013; 24: 1175-1181.
42. Kiberd BA, Clase CM. Cumulative risk for developing end-stage renal disease in the US population. J Am Soc Nephrol 2002; 13: 1635-1644.
43. Genovese G, Friedman DJ, Ross MD et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329: 841-845.
44. Lipkowitz MS, Freedman BI, Langefeld CD et al. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int 2013; 83: 114-120.
45. Fogo A, Breyer JA, Smith MC et al. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators. Kidney Int 1997; 51: 244-252.
46. Ponticelli C, Glassock RJ. Posttransplant recurrence of primary glomerulonephritis. Clin J Am Soc Nephrol 2010; 5: 2363-2372.
47. Noris M, Remuzzi G. Thrombotic microangiopathy after kidney transplantation. Am J Transplant 2010; 10: 1517-1523.
48. Nankivell BJ, Alexander SI. Rejection of the kidney allograft. New Engl J Med 2010; 363: 1451-1462.
49. Henderson LK, Nankivell BJ, Chapman JR. Surveillance protocol kidney transplant biopsies: their evolving role in clinical practice. Am J Transplant 2011; 11: 1570-1575.
50. Seemayer CA, Gaspert A, Nickeleit V et al. C4d staining of renal allograft biopsies: a comparative analysis of different staining techniques. Nephrol Dial Transplant 2007; 22: 568-576.
51. Zou Y, Stastny P, Susal C et al. Antibodies against MICA antigens and kidney-transplant rejection. New Engl J Med 2007; 357: 1293-1300.
52. Wei C, El Hindi S, Li J et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011; 17: 952-960.
53. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis-A new look at an old entity. New Engl J Med 2012; 366: 1119-1131.
54. Roberts IS, Cook HT, Troyanov S et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009; 76: 546-556.
55. Cattran DC, Coppo R, Cook HT et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009; 76: 534-545.
56. Katafuchi R, Ikeda K, Mizumasa T et al. Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy. Am J Kidney Dis 2003; 41: 972-983.
57. Gutierrez E, Zamora I, Ballarin JA et al. Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. J Am Soc Nephrol 2012; 23: 1753-1760.
58. Roberts IS. Oxford classification of immunoglobulin A nephropathy: an update. Curr Opin Nephrol Hypertens 2013 (e-pub ahead of print).
59. Yau T, Korbet SM, Schwartz MM et al. The Oxford classification of IgA nephropathy: a retrospective analysis. Am J Nephrol 2011; 34: 435-444.
60. Furuta S, Jayne DR. Antineutrophil cytoplasm antibody-associated vasculitis: recent developments. Kidney Int 2013; 84: 244-249.
61. Mukhtyar C, Flossmann O, Hellmich B et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008; 67: 1004-1010.
62. Bajema IM, Hagen EC, Hermans J et al. Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. Kidney Int 1999; 56: 1751-1758.
63. de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R et al. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: a prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol 2006; 17: 2264-2274.
64. Berden AE, Ferrario F, Hagen EC et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 2010; 21: 1628-1636.
65. Berden AE, Jones RB, Erasmus DD et al. Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy. J Am Soc Nephrol 2012; 23: 313-321.
66. Xing GQ, Chen M, Liu G et al. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J Clin Immunol 2009; 29: 282-291.
67. Xing GQ, Chen M, Liu G et al. Differential deposition of C4d and MBL in glomeruli of patients with ANCA-negative pauci-immune crescentic glomerulonephritis. J Clin Immunol 2010; 30: 144-156.
68. Hewitt SM, Dear J, Star RA. Discovery of protein biomarkers for renal diseases. J Am Soc Nephrol 2004; 15: 1677-1689.
69. Markowitz GS, D'Agati VD. Classification of lupus nephritis. Curr Opin Nephrol Hypertens 2009; 18: 220-225.
70. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241-250.
71. Gunnarsson I, Sundelin B, Jonsdottir T et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamideresistant proliferative lupus nephritis. Arthritis Rheum 2007; 56: 1263-1272.
72. Lightstone L. Lupus nephritis: where are we now? Curr Opin Rheum 2010; 22: 252-256.
73. Pagni F, Galimberti S, Goffredo P et al. The value of repeat biopsy in the management of lupus nephritis: an international multicentre study in a large cohort of patients. Nephrol Dial Transplant 2013; 28: 3014-3023.
74. Daleboudt GM, Bajema IM, Goemaere NN et al. The clinical relevance of a repeat biopsy in lupus nephritis flares. Nephrol Dial Transplant 2009; 24: 3712-3717.
75. Lu J, Tam LS, Lai FM et al. Repeat renal biopsy in lupus nephritis: a change in histological pattern is common. Am J Nephrol 2011; 34: 220-225.
76. Munivenkatappa RB, Schweitzer EJ, Papadimitriou JC et al. The Maryland aggregate pathology index: a deceased donor kidney biopsy scoring system for predicting graft failure. Am J Transplant 2008; 8: 2316-2324.
77. Chapman JR. Longitudinal analysis of chronic allograft nephropathy: clinicopathologic correlations. Kidney Int 2005; S108-S112.
78. Pascual M, Vallhonrat H, Cosimi AB et al. The clinical usefulness of the renal allograft biopsy in the cyclosporine era: a prospective study. Transplantation 1999; 67: 737-741.
79. Ewis AA, Zhelev Z, Bakalova R et al. A history of microarrays in biomedicine. Exp Rev Mol Diag 2005; 5: 315-328.
80. Chandrasekaran K, Karolina DS, Sepramaniam S et al. Role of microRNAs in kidney homeostasis and disease. Kidney Int 2012; 81: 617-627.
81. Williams WW, Taheri D, Tolkoff-Rubin N et al. Clinical role of the renal transplant biopsy. Nature Rev Nephrol 2012; 8: 110-121.
82. Halloran PF, de Freitas DG, Einecke G et al. An integrated view of molecular changes, histopathology and outcomes in kidney transplants. Am J Transplant 2010; 10: 2223-2230.
83. Waikar SS, Betensky RA, Emerson SC et al. Imperfect gold standards for kidney injury biomarker evaluation. J Am Soc Nephrol 2012; 23: 13-21.
84. Beck LH Jr., Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. New Engl J Med 2009; 361: 11-21.
85. Qin W, Beck LH Jr., Zeng C et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol 2011; 22: 1137-1143.
86. Hoxha E, Kneissler U, Stege G et al. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int 2012; 82: 797-804.
87. Beck LH Jr., Fervenza FC, Beck DM et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011; 22: 1543-1550.
88. Howman A, Chapman TL, Langdon MM et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet 2013; 381: 744-751.
89. Waldman M, Austin HA 3rd. Treatment of idiopathic membranous nephropathy. J Am Soc Nephrol 2012; 23: 1617-1630.
90. Larsen CP, Walker PD. Phospholipase A2 receptor (PLA2R) staining is useful in the determination of de novo versus recurrent membranous glomerulopathy. Transplantation 2013; 95: 1259-1262.
91. Debiec H, Martin L, Jouanneau C et al. Autoantibodies specific for the phospholipase A2 receptor in recurrent and De Novo membranous nephropathy. Am J Transplant 2011; 11: 2144-2152.
92. Hodgin JB, Borczuk AC, Nasr SH et al. A molecular profile of focal segmental glomerulosclerosis from formalin-fixed, paraffin-embedded tissue. Am J Pathol 2010; 177: 1674-1686.
93. Sethi S, Vrana JA, Theis JD et al. Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis. Kidney Int 2012; 82: 226-234.
94. Sethi S, Vrana JA, Theis JD et al. Mass spectrometry based proteomics in the diagnosis of kidney disease. Curr Opin Nephrol Hypertens 2013 (e-pub ahead of print).
95. Nasr SH, Satoskar A, Markowitz GS et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol 2009; 20: 2055-2064.
96. Raissian Y, Nasr SH, Larsen CP et al. Diagnosis of IgG4-related tubulointerstitial nephritis. J Am Soc Nephrol 2011; 22: 1343-1352.
97. Parving HH, Gall MA, Skott P et al. Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int 1992; 41: 758-762.